Month: August 2020

MONTRÉAL, 12 août 2020 (GLOBE NEWSWIRE) — TFI International Inc. (NYSE et TSX : TFII), chef de file nord-américain de l’industrie du transport et de la logistique, a annoncé aujourd’hui le prix de son placement négocié précédemment annoncé aux États‑Unis et au Canada et que la taille du placement a été augmentée pour atteindre 4 400 000 actions ordinaires. TFI International émettra les actions au prix unitaire de 43,25 $ US, soit l’équivalent de 57,32 $ CA par action, selon le taux de change actuel de la Banque du Canada, pour un produit brut de 190 300 000 $ US à TFI International. La clôture du placement est prévue le 17 août 2020, sous réserve des conditions de clôture habituelles.Le placement auprès du public est réalisé par un syndicat de preneurs fermes dirigé par Morgan Stanley, BofA Securities, Credit Suisse, Goldman Sachs...

MONTREAL, Aug. 12, 2020 (GLOBE NEWSWIRE) — TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced the pricing of its previously-announced marketed offering in the United States and Canada and that the size of the offering has been increased to 4,400,000 common shares. TFI International will issue the shares at a price of US $43.25 per share, the equivalent of CAD $57.32 per share based on today’s Bank of Canada exchange rate, for gross proceeds of US $190,300,000. The offering is expected to close on August 17, 2020, subject to customary closing conditions.The public offering is being conducted through a syndicate of underwriters led by Morgan Stanley, BofA Securities, Credit Suisse, Goldman Sachs & Co. LLC and J.P. Morgan, as joint lead book-running...

VANCOUVER, British Columbia, Aug. 12, 2020 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company”) (TSX:III) reports financial results for the three and six months ended June 30, 2020, as summarized in this release and discussed in detail in the Management’s Discussion & Analysis. The Company’s financial results are prepared in accordance with International Financial Reporting Standards. The reporting currency of the Company is the Canadian (“CDN”) Dollar.QUARTER HIGHLIGHTSFINANCIALOn February 20, 2019, the Company initiated a process for the sale of the Red Chris mine and in accordance with IFRS, the Company classified Red Chris mine as a discontinued operation effective January 1, 2019 up until the closing of the transaction with Newcrest on August 14, 2019. Effective August 15, 2019 the results from the Red Chris...

CALGARY, Alberta, Aug. 12, 2020 (GLOBE NEWSWIRE) — Painted Pony Energy Ltd. (“Painted Pony” or the “Corporation”) (TSX: PONY) announces second quarter 2020 financial and operating results.HIGHLIGHTSAnnounced an agreement to be acquired by Canadian Natural Resources Limited for $0.69 per share, representing a 30% premium to the 20-day volume weighted average price of $0.53 per share at the time of the announcement on Monday, August 10, 2020; Averaged daily production of 305,058 Mcfe/d (50,843 boe/d) during the second quarter of 2020 compared to 293,868 Mcfe/d (48,978 boe/d) during the second quarter of 2019, and; Produced average daily liquids of 4,396 bbls/d during the second quarter of 2020, which was 22% higher than liquids production of 3,594 bbls/d during the first quarter of 2020, and compares to second quarter 2019 liquids...

HOUSTON, Aug. 12, 2020 (GLOBE NEWSWIRE) — Occidental (NYSE: OXY) today announced that, in connection with its offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) the outstanding senior notes listed in the table below and Consent Solicitations (as defined below), it is increasing (i) the maximum aggregate purchase price of Notes (as defined below) it will accept for purchase, excluding accrued but unpaid interest (as amended herein, the “Maximum Aggregate Purchase Price”), from the previously announced amount of $1,500 million to $3,000 million and (ii) the maximum aggregate purchase price of 2022 Notes (as defined below) it will accept for purchase, excluding accrued but unpaid interest (as amended herein, the “2022 Notes Sub-Cap”), from the previously announced amount of $200 million to $700...

SAN DIEGO, Aug. 12, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) announced today that it believes it has uncovered fraudulent attempts to manipulate the Company’s stock.On August 11, 2020, it was reported that an organization calling itself “Hindenburg Research” published claims regrading one of Sorrento’s COVID-19 diagnostic products. The report is believed to include false and/or misleading statements for the sole apparent purpose of negatively manipulating the company’s stock price.Sorrento will collaborate with law enforcement and regulators to ensure that any criminal activity is investigated and rectified.  Sorrento, through its legal counsel, Paul Hastings LLP, has demanded that the organization cease and desist from illegal and wrongful activity and retract false and/or misleading...

– Financial results to be released after markets on Thursday, August 20, 2020 –TORONTO, Aug. 12, 2020 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV: FW) (“Flow Capital” and “Company”) today announced it will release its 2020 second quarter financial results after the markets close on Thursday, August 20, 2020. Mr. Alex Baluta, Chief Executive Officer, and Mr. Gaurav Singh, Chief Financial Officer, will host a conference call at 8:30 a.m. ET, on Friday, August 21, 2020, to review the results. A question and answer session will follow the corporate update.A recording of the call will be archived on the Company’s website at www.flowcap.com/financials/.For further information, please contact:

TORONTO, Aug. 12, 2020 (GLOBE NEWSWIRE) — Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today reported financial results for three and six months ended June 30, 2020. All dollar amounts are in Canadian dollars, unless otherwise stated.“Our business has demonstrated resilience during the first half of the year amidst the challenges presented to the economy as a result of the COVID-19 pandemic,” said Mike Crawley, Northland’s President and Chief Executive Officer. “We are pleased with the financial results of our business and are extremely proud of how our employees have responded to the crisis.” “Our efforts remain focused on ensuring our employees, contractors and communities across our global operations are safe and healthy, while continuing to deliver our essential services. During the period, we strengthened...

Ascatron AB – Kista, Sweden: Silicon carbide (SiC) epitaxial wafers and devices for power electronicsINNOViON Corporation – Colorado Springs, CO, U.S.: Ion implantation technology and services for semiconductor devicesTransactions expected to close by the end of calendar year 2020Acquisitions complement the technology licensed from General Electric (NYSE: GE) to manufacture SiC devices and modules for power electronicsPITTSBURGH, Aug. 12, 2020 (GLOBE NEWSWIRE) — II-VI Incorporated (Nasdaq: IIVI), a leader in compound semiconductors, today announced that it has entered into a definitive agreement to acquire all the outstanding shares of Ascatron AB, a leader in silicon carbide (SiC) epitaxial wafers and devices for power electronics. II-VI also announced that it will acquire all the outstanding interests of the owners...

针对opaganib的全球2/3期研究计划在40个临床地点招募270名新冠肺炎重症患者——全球2/3期研究已在墨西哥、英国和俄罗斯，在意大利和巴西等其他一些国家正在接受审核——在美国的一项针对重症新冠肺炎患者的2期平行研究的患者招募工作已完成约50%，预计将于本月完成——计划最早在2020年第4季度提交全球紧急用药申请以色列特拉维夫和北卡罗来纳州罗利, Aug. 13, 2020 (GLOBE NEWSWIRE) — 特种生物制药企业RedHill Biopharma Ltd.（纳斯达克：RDHL）（以下称“RedHill”或该“公司”）今天宣布，墨西哥联邦卫生风险保护委员会（COFEPRIS）已批准该公司的临床试验授权（CTA）申请以进行2/3阶段研究，评估opaganib（Yeliva®，ABC294640）1对重度SARS-CoV-2（新型冠状病毒）感染（新冠肺炎的致病原因）和肺炎住院患者的疗效。RedHill的研究目前已在墨西哥、英国和俄罗斯获得批准，并正在意大利、巴西和其他国家接受审核。目前已制定计划将这项研究进一步扩展到更多国家。“随着新出现的感染激增并带来新的重症病例，药物开发人员必须以严格设计和迅速实施的研究作出响应。opaganib是目前正在试验用于重症新冠肺炎患者的最先进的新型药物之一，”RedHill首席运营官Gilead Raday表示。 “与此同时，我们预计在本月完成正在美国进行的opaganib二期研究的患者招募。如果上述研究成功，我们将力争最早在今年第四季度申请紧急用药授权。”这是一项多中心、随机、双盲、平行、安慰剂对照的2/3期研究（NCT04467840），计划招募270名需要住院治疗和辅助供氧的新冠肺炎重症患者参与试验。受试者将以1:1的比例随机分组，接受opaganib或安慰剂用药，并按医护标准接受治疗。该研究的主要终点是评估在第14天时需要插管和呼吸机的患者比例。在大约100名受试者接受主要终点评估之后，一家独立数据安全监测委员会（DSMB）将进行解盲无效中期分析。与此同时，在美国进行的opaganib二期临床研究的患者招募已完成约50%，预计将在本月全部完成。这项随机、双盲的安慰剂对照研究（NCT04414618）并非以统计显著性为目标，旨在招募40名需要住院治疗和辅助吸氧的新冠肺炎重症患者参与试验。关于opaganib（ABC294640，Yeliva®）opaganib是一种新的化学体，一种专有的首创性口服鞘氨醇激酶-2（SK2）选择性抑制剂，具有抗肿瘤、抗炎和抗病毒活性，针对多种肿瘤、病毒、炎症和肠道适应症。通过抑制SK2，opaganib可影响与癌细胞生长、病毒复制和病理炎症相关的多种蜂窝路径。opaganib最初由美国Apogee...